US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

50.23

-1.5700-3.03%

Post-market: 50.18-0.0500-0.10%19:48 EST

Volume:992.42K

Turnover:49.72M

Market Cap:2.03B

PE:-4.52

High:51.15

Open:50.00

Low:49.26

Close:51.80

52wk High:118.84

52wk Low:20.44

Shares:40.33M

Float Shares:34.19M

Volume Ratio:0.75

T/O Rate:2.90%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-11.1105

EPS(LYR):-11.1105

ROE:-16.07%

ROA:-11.31%

PB:0.79

PE(LYR):-4.52

Loading ...

Overview Company News Filings

Stock Track | GRAIL, Inc. Plunges 30.09% After-Hours as Key Trial Endpoint Misses Target

GRAIL FY 2025 net loss was USD 408.4 million, improving 80%

GRAIL Q4 EPS $(2.44) Beats $(2.73) Estimate, Sales $43.597M Miss $43.600M Estimate

Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses

Grail Inc: Primary Endpoint of Statistically Significant Combined Stage Iii-Iv Reduction Was Not Met

THOMSON REUTERS

Landmark Nhs-Galleri Trial Demonstrates a Substantial Reduction in Stage Iv Cancer Diagnoses, Increased Stage I and Ii Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

THOMSON REUTERS

Grail Inc: Plans to Extend Trial's Follow up Period by 6-12 Months

THOMSON REUTERS

Grail Inc : TD Cowen Initiates Coverage With Hold Rating; Price Target $114

THOMSON REUTERS

Balancing Market Leadership and Regulatory Risk: Justifying a Hold Rating After a 450% Rally

Baird Initiates GRAIL at Outperform With $113 Price Target

MT Newswires Live

Grail Initiated at Outperform by Baird

Grail initiated with an Outperform at Baird

Grail Inc. to Announce Fourth Quarter and Full Year Financial Results

Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. -- Barrons.com

Hims & Hers Health kooperiert mit GRAIL für Multi-Krebs-Früherkennungstest

Grail submits FDA premarket approval appplication for Galleri

Grail Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Test

Grail Is Maintained at Buy by Guggenheim

Grail falls -9.2%

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and GRAIL Inc (GRAL)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GRAL/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRAL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","market":"US","secType":"STK","nameCN":"GRAIL, Inc.","latestPrice":50.23,"timestamp":1772830800000,"preClose":51.8,"halted":0,"volume":992419,"hourTrading":{"tag":"盘后","latestPrice":50.18,"preClose":50.23,"latestTime":"19:48 EST","volume":16273,"amount":817480.0574,"timestamp":1772844536324,"change":-0.05,"changeRate":-0.000995,"amplitude":0.00918},"delay":0,"changeRate":-0.030308880308880317,"floatShares":34193700,"shares":40331400,"eps":-11.110457,"marketStatus":"Market Closed","change":-1.57,"latestTime":"03-06 16:00:00 EST","open":50,"high":51.15,"low":49.26,"amount":49723228.702139996,"amplitude":0.036486,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11.110457,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773043200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":51.8,"preHourTrading":{"tag":"盘前","latestPrice":49.97,"preClose":51.8,"latestTime":"09:29 EST","volume":20918,"amount":1039370.86466,"timestamp":1772807363131,"change":-1.83,"changeRate":-0.035328,"amplitude":0.044274},"postHourTrading":{"tag":"盘后","latestPrice":50.18,"preClose":50.23,"latestTime":"19:48 EST","volume":16273,"amount":817480.0574,"timestamp":1772844536324,"change":-0.05,"changeRate":-0.000995,"amplitude":0.00918},"volumeRatio":0.7546867263061057,"impliedVol":0.9302,"impliedVolPercentile":0.3705},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","floatShares":34193700,"roa":"-11.31%","roe":"-16.07%","lyrEps":-11.110457,"volumeRatio":0.7546867263061057,"shares":40331400,"dividePrice":0,"high":51.15,"amplitude":0.036486,"preClose":51.8,"low":49.26,"week52Low":20.44,"pbRate":"0.79","psRate":"13.77","week52High":118.84,"institutionHeld":0,"latestPrice":50.23,"eps":-11.110457,"divideRate":0,"volume":992419,"delay":0,"ttmEps":-11.110457,"open":50,"prevYearClose":85.59,"prevWeekClose":53.23,"prevMonthClose":53.23,"prevQuarterClose":85.59,"fiveDayClose":53.23,"twentyDayClose":94.06,"sixtyDayClose":99.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRAL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"GRAL","fiscalQuarterEnding":"2025/12","expectedEps":-3.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":-1.86},{"market":"US","date":"2025-11-12","symbol":"GRAL","fiscalQuarterEnding":"2025/09","expectedEps":-3.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-2.46},{"market":"US","date":"2025-08-12","symbol":"GRAL","fiscalQuarterEnding":"2025/06","expectedEps":-3.14,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-3.18},{"market":"US","date":"2025-05-13","symbol":"GRAL","fiscalQuarterEnding":"2025/03","expectedEps":-4.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-3.1},{"market":"US","date":"2025-02-20","symbol":"GRAL","fiscalQuarterEnding":"2024/12","expectedEps":-4.41,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"post","actualEps":-1.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRAL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRAL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.1667,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.1667,"analysts":6,"updateTime":1771563600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRAL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRAL","date":"2026-03-06","current":-4.520966,"percent":0.242054,"low":-11.136928,"twenty":-6.525603,"median":-0.645131,"eighty":-0.273298,"high":-0.135365,"avg":-2.663017,"sd":3.442658,"marketCap":2089164448},"quantilePoints":[{"date":"2024-06-12","current":-0.243184,"twenty":-0.243184,"median":-0.243184,"eighty":-0.243184,"marketCap":362571424},{"date":"2024-06-28","current":-0.269888,"twenty":-0.264547,"median":-0.256536,"eighty":-0.248525,"marketCap":402385270},{"date":"2024-07-05","current":-0.275763,"twenty":-0.275763,"median":-0.271757,"eighty":-0.266328,"marketCap":411144316},{"date":"2024-07-12","current":-0.259385,"twenty":-0.273627,"median":-0.266328,"eighty":-0.249504,"marketCap":386725157},{"date":"2024-07-15","current":-0.263657,"twenty":-0.273022,"median":-0.264992,"eighty":-0.25148,"marketCap":393095372},{"date":"2024-08-02","current":-0.296236,"twenty":-0.274909,"median":-0.266328,"eighty":-0.253456,"marketCap":441668264},{"date":"2024-08-09","current":-0.310656,"twenty":-0.300615,"median":-0.272114,"eighty":-0.260667,"marketCap":463167741},{"date":"2024-08-16","current":-0.170902,"twenty":-0.29588,"median":-0.2706,"eighty":-0.248276,"marketCap":492749978},{"date":"2024-08-23","current":-0.178117,"twenty":-0.292284,"median":-0.264992,"eighty":-0.180551,"marketCap":513552907},{"date":"2024-08-30","current":-0.159595,"twenty":-0.28292,"median":-0.259385,"eighty":-0.170708,"marketCap":460148373},{"date":"2024-09-06","current":-0.145057,"twenty":-0.275763,"median":-0.247457,"eighty":-0.162201,"marketCap":418232023},{"date":"2024-09-13","current":-0.145918,"twenty":-0.275336,"median":-0.18151,"eighty":-0.152854,"marketCap":420715955},{"date":"2024-09-20","current":-0.149365,"twenty":-0.273627,"median":-0.178117,"eighty":-0.150075,"marketCap":430651682},{"date":"2024-09-27","current":-0.146457,"twenty":-0.273022,"median":-0.170741,"eighty":-0.146026,"marketCap":422268412},{"date":"2024-10-04","current":-0.135365,"twenty":-0.270458,"median":-0.165733,"eighty":-0.14454,"marketCap":390287790},{"date":"2024-10-11","current":-0.140319,"twenty":-0.269176,"median":-0.160133,"eighty":-0.142925,"marketCap":404570398},{"date":"2024-10-18","current":-0.152918,"twenty":-0.265794,"median":-0.156041,"eighty":-0.143463,"marketCap":440897901},{"date":"2024-10-25","current":-0.13978,"twenty":-0.263443,"median":-0.155556,"eighty":-0.143463,"marketCap":403017941},{"date":"2024-10-31","current":-0.146672,"twenty":-0.262589,"median":-0.153942,"eighty":-0.142688,"marketCap":422889395},{"date":"2024-11-08","current":-0.160456,"twenty":-0.259385,"median":-0.152918,"eighty":-0.142796,"marketCap":462632305},{"date":"2024-11-15","current":-0.250879,"twenty":-0.250879,"median":-0.154641,"eighty":-0.143442,"marketCap":531228205},{"date":"2024-11-22","current":-0.259924,"twenty":-0.250879,"median":-0.156041,"eighty":-0.143549,"marketCap":550380645},{"date":"2024-11-29","current":-0.277697,"twenty":-0.262044,"median":-0.156472,"eighty":-0.143635,"marketCap":588013510},{"date":"2024-12-06","current":-0.355611,"twenty":-0.27003,"median":-0.160025,"eighty":-0.14426,"marketCap":752993300},{"date":"2024-12-13","current":-0.329745,"twenty":-0.275763,"median":-0.161318,"eighty":-0.144928,"marketCap":698224042},{"date":"2024-12-20","current":-0.271984,"twenty":-0.27776,"median":-0.165841,"eighty":-0.145746,"marketCap":575917232},{"date":"2024-12-27","current":-0.308005,"twenty":-0.287312,"median":-0.170741,"eighty":-0.145918,"marketCap":652190984},{"date":"2025-01-03","current":-0.284362,"twenty":-0.289787,"median":-0.175532,"eighty":-0.146134,"marketCap":602125834},{"date":"2025-01-10","current":-0.280236,"twenty":-0.294514,"median":-0.180594,"eighty":-0.1465,"marketCap":593389633},{"date":"2025-01-17","current":-0.276189,"twenty":-0.293978,"median":-0.222157,"eighty":-0.146801,"marketCap":584821436},{"date":"2025-01-24","current":-0.412102,"twenty":-0.295346,"median":-0.234852,"eighty":-0.147318,"marketCap":872612048},{"date":"2025-01-31","current":-0.500013,"twenty":-0.298484,"median":-0.241319,"eighty":-0.14818,"marketCap":1058760325},{"date":"2025-02-07","current":-0.523498,"twenty":-0.307212,"median":-0.249504,"eighty":-0.148826,"marketCap":1108489468},{"date":"2025-02-14","current":-0.83436,"twenty":-0.31102,"median":-0.255132,"eighty":-0.149365,"marketCap":1766728591},{"date":"2025-02-21","current":-0.791697,"twenty":-0.321747,"median":-0.260916,"eighty":-0.149365,"marketCap":1604772870},{"date":"2025-02-28","current":-0.656882,"twenty":-0.34371,"median":-0.263657,"eighty":-0.149709,"marketCap":1331502572},{"date":"2025-03-07","current":-0.559345,"twenty":-0.359577,"median":-0.270244,"eighty":-0.149795,"marketCap":1133795978},{"date":"2025-03-14","current":-0.450152,"twenty":-0.414561,"median":-0.273627,"eighty":-0.15014,"marketCap":912460022},{"date":"2025-03-21","current":-0.465034,"twenty":-0.450921,"median":-0.275763,"eighty":-0.150484,"marketCap":942626791},{"date":"2025-03-28","current":-0.47791,"twenty":-0.468947,"median":-0.276427,"eighty":-0.150807,"marketCap":968726130},{"date":"2025-04-04","current":-0.416039,"twenty":-0.465703,"median":-0.277856,"eighty":-0.15113,"marketCap":843313720},{"date":"2025-04-11","current":-0.380338,"twenty":-0.459122,"median":-0.280236,"eighty":-0.151281,"marketCap":770947370},{"date":"2025-04-17","current":-0.443129,"twenty":-0.455455,"median":-0.281347,"eighty":-0.151562,"marketCap":898224019},{"date":"2025-04-25","current":-0.630246,"twenty":-0.466372,"median":-0.283965,"eighty":-0.151863,"marketCap":1277511821},{"date":"2025-05-02","current":-0.565758,"twenty":-0.478944,"median":-0.287218,"eighty":-0.15253,"marketCap":1146794916},{"date":"2025-05-09","current":-0.62862,"twenty":-0.498389,"median":-0.292296,"eighty":-0.15337,"marketCap":1274216573},{"date":"2025-05-16","current":-0.732698,"twenty":-0.51302,"median":-0.295346,"eighty":-0.153995,"marketCap":1402606531},{"date":"2025-05-23","current":-0.728564,"twenty":-0.527433,"median":-0.296725,"eighty":-0.154728,"marketCap":1394692362},{"date":"2025-05-30","current":-0.772349,"twenty":-0.542338,"median":-0.298484,"eighty":-0.155417,"marketCap":1478510603},{"date":"2025-06-06","current":-0.742094,"twenty":-0.562722,"median":-0.305137,"eighty":-0.155977,"marketCap":1420593278},{"date":"2025-06-13","current":-0.787758,"twenty":-0.602918,"median":-0.308322,"eighty":-0.156041,"marketCap":1508008868},{"date":"2025-06-20","current":-0.910282,"twenty":-0.617043,"median":-0.310838,"eighty":-0.156127,"marketCap":1742556049},{"date":"2025-06-27","current":-0.927946,"twenty":-0.628237,"median":-0.313683,"eighty":-0.156967,"marketCap":1776371133},{"date":"2025-07-03","current":-0.87796,"twenty":-0.640897,"median":-0.324667,"eighty":-0.158949,"marketCap":1680681639},{"date":"2025-07-11","current":-0.815382,"twenty":-0.656882,"median":-0.33641,"eighty":-0.159595,"marketCap":1560889904},{"date":"2025-07-18","current":-0.675007,"twenty":-0.694504,"median":-0.351643,"eighty":-0.160456,"marketCap":1292167904},{"date":"2025-07-25","current":-0.746416,"twenty":-0.703946,"median":-0.35847,"eighty":-0.160672,"marketCap":1428867181},{"date":"2025-08-01","current":-0.642872,"twenty":-0.704698,"median":-0.372061,"eighty":-0.161318,"marketCap":1230653229},{"date":"2025-08-08","current":-0.619382,"twenty":-0.703946,"median":-0.384644,"eighty":-0.164764,"marketCap":1185686362},{"date":"2025-08-15","current":-2.618835,"twenty":-0.718416,"median":-0.412102,"eighty":-0.165733,"marketCap":1160018171},{"date":"2025-08-22","current":-2.697774,"twenty":-0.721799,"median":-0.415789,"eighty":-0.165949,"marketCap":1194984536},{"date":"2025-08-29","current":-2.7759,"twenty":-0.732698,"median":-0.419718,"eighty":-0.170579,"marketCap":1229590423},{"date":"2025-09-05","current":-2.733582,"twenty":-0.742958,"median":-0.427076,"eighty":-0.170837,"marketCap":1210845568},{"date":"2025-09-12","current":-3.145369,"twenty":-0.751941,"median":-0.435395,"eighty":-0.172539,"marketCap":1393247431},{"date":"2025-09-19","current":-3.221867,"twenty":-0.757193,"median":-0.443129,"eighty":-0.177083,"marketCap":1427132362},{"date":"2025-09-26","current":-3.927439,"twenty":-0.772199,"median":-0.450236,"eighty":-0.179927,"marketCap":1739666779},{"date":"2025-10-03","current":-5.267781,"twenty":-0.790326,"median":-0.453995,"eighty":-0.180724,"marketCap":2333374029},{"date":"2025-10-10","current":-5.788618,"twenty":-0.792794,"median":-0.466707,"eighty":-0.18193,"marketCap":2564079942},{"date":"2025-10-17","current":-7.032117,"twenty":-0.810572,"median":-0.474733,"eighty":-0.214168,"marketCap":3114890311},{"date":"2025-10-24","current":-6.726125,"twenty":-0.834423,"median":-0.483801,"eighty":-0.232186,"marketCap":2979350587},{"date":"2025-10-31","current":-7.417862,"twenty":-0.86879,"median":-0.497307,"eighty":-0.23482,"marketCap":3285756878},{"date":"2025-11-07","current":-6.515349,"twenty":-0.90953,"median":-0.508594,"eighty":-0.23627,"marketCap":2885986787},{"date":"2025-11-14","current":-7.32206,"twenty":-1.284423,"median":-0.515869,"eighty":-0.238888,"marketCap":3243320953},{"date":"2025-11-21","current":-8.218834,"twenty":-2.622741,"median":-0.524768,"eighty":-0.242438,"marketCap":3338827399},{"date":"2025-11-28","current":-10.592844,"twenty":-2.668803,"median":-0.533066,"eighty":-0.245748,"marketCap":4303247596},{"date":"2025-12-05","current":-10.047321,"twenty":-2.733908,"median":-0.545714,"eighty":-0.248685,"marketCap":4081633659},{"date":"2025-12-12","current":-9.121802,"twenty":-2.773947,"median":-0.559678,"eighty":-0.249586,"marketCap":3705650118},{"date":"2025-12-19","current":-8.474563,"twenty":-3.023948,"median":-0.565758,"eighty":-0.250383,"marketCap":3442715024},{"date":"2025-12-26","current":-8.814736,"twenty":-3.115583,"median":-0.600672,"eighty":-0.254281,"marketCap":3580907004},{"date":"2026-01-02","current":-8.213077,"twenty":-3.191837,"median":-0.607471,"eighty":-0.259493,"marketCap":3336488466},{"date":"2026-01-09","current":-9.407758,"twenty":-3.756539,"median":-0.615248,"eighty":-0.260321,"marketCap":3821817142},{"date":"2026-01-16","current":-9.350183,"twenty":-4.63773,"median":-0.618067,"eighty":-0.262044,"marketCap":3798427809},{"date":"2026-01-23","current":-11.136928,"twenty":-5.050494,"median":-0.621638,"eighty":-0.262589,"marketCap":4524276801},{"date":"2026-01-30","current":-9.689876,"twenty":-5.381714,"median":-0.623725,"eighty":-0.263657,"marketCap":3936424878},{"date":"2026-02-06","current":-9.025844,"twenty":-5.92371,"median":-0.62862,"eighty":-0.266328,"marketCap":3666667895},{"date":"2026-02-13","current":-9.201448,"twenty":-6.490935,"median":-0.634416,"eighty":-0.269888,"marketCap":3738005363},{"date":"2026-02-20","current":-10.027753,"twenty":-6.738169,"median":-0.640672,"eighty":-0.270458,"marketCap":4094842980},{"date":"2026-02-27","current":-5.738328,"twenty":-6.59852,"median":-0.642551,"eighty":-0.271707,"marketCap":2343252016},{"date":"2026-03-06","current":-5.1161,"twenty":-6.525603,"median":-0.645131,"eighty":-0.273298,"marketCap":2089164448}],"updateTime":1772901856553},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRAL\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1169766564","title":"Stock Track | GRAIL, Inc. Plunges 30.09% After-Hours as Key Trial Endpoint Misses Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1169766564","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169766564?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:33","pubTimestamp":1771536838,"startTime":"0","endTime":"0","summary":"GRAIL, Inc. (NASDAQ: GRAL) experienced a sharp decline of 30.09% in after-hours trading following the release of its fourth-quarter financial results and pivotal trial data.The stock's steep drop...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GRAL"],"gpt_icon":0},{"id":"2612238321","title":"GRAIL FY 2025 net loss was USD 408.4 million, improving 80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238321","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238321?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:03","pubTimestamp":1771535002,"startTime":"0","endTime":"0","summary":"GRAIL FY 2025 net loss was USD 408.4 million, improving 80%               GRAIL reported Q4 2025 total revenue of USD 43.6 million (+14% YoY), including U.S. Galleri revenue of USD 41.3 million (+31% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL796wBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4588","HIYY","GRAL","HIMY","BK4535","HMYY","HIMZ","BK4139","BK4534","BK4121","BK4196","BK4585"],"gpt_icon":0},{"id":"2612238340","title":"GRAIL Q4 EPS $(2.44) Beats $(2.73) Estimate, Sales $43.597M Miss $43.600M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238340","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238340?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:03","pubTimestamp":1771534982,"startTime":"0","endTime":"0","summary":"GRAIL (NASDAQ:GRAL) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.73) by 10.62 percent. This is a 15.57 percent increase over losses of $(2.89) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50734254/grail-q4-eps-2-44-beats-2-73-estimate-sales-43-597m-miss-43-600m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL Q4 EPS $(2.44) Beats $(2.73) Estimate, Sales $43.597M Miss $43.600M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2612238878","title":"Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238878","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238878?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:01","pubTimestamp":1771534897,"startTime":"0","endTime":"0","summary":"Grail Inc. announced topline results from the randomized, controlled NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test in 142,000 participants aged 50–77 in England’s NHS over three years. The trial did not meet its primary endpoint of a statistically significant combined Stage III–IV reduction, but reported reductions in Stage IV diagnoses over sequential screening rounds  in a pre-specified group of 12 cancers, along with increased detection of Stage I–II cancers and a four-fold improvement in overall cancer detection rate versus standard screening alone. Detailed results have not yet been presented and are planned for submission for presentation at the ASCO 2026 Annual Meeting.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL82JSK4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2612388802","title":"Grail Inc: Primary Endpoint of Statistically Significant Combined Stage Iii-Iv Reduction Was Not Met","url":"https://stock-news.laohu8.com/highlight/detail?id=2612388802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612388802?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:01","pubTimestamp":1771534860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA5XBTPW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2612238862","title":"Landmark Nhs-Galleri Trial Demonstrates a Substantial Reduction in Stage Iv Cancer Diagnoses, Increased Stage I and Ii Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238862?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:01","pubTimestamp":1771534860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA5XBTPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2612238861","title":"Grail Inc: Plans to Extend Trial's Follow up Period by 6-12 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238861?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:01","pubTimestamp":1771534860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA5XBTPW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2612020984","title":"Grail Inc : TD Cowen Initiates Coverage With Hold Rating; Price Target $114","url":"https://stock-news.laohu8.com/highlight/detail?id=2612020984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612020984?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:31","pubTimestamp":1771504292,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF14J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2612409287","title":"Balancing Market Leadership and Regulatory Risk: Justifying a Hold Rating After a 450% Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2612409287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612409287?lang=en_us&edition=fundamental","pubTime":"2026-02-19 18:45","pubTimestamp":1771497922,"startTime":"0","endTime":"0","summary":"GRAIL Inc (GRAL) has received a new Hold rating, initiated by TD Cowen analyst, Daniel Brennan. Daniel Brennan has given his Hold rating due to a c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balancing-market-leadership-and-regulatory-risk-justifying-a-hold-rating-after-a-450-rally-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balancing-market-leadership-and-regulatory-risk-justifying-a-hold-rating-after-a-450-rally-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2612545154","title":"Baird Initiates GRAIL at Outperform With $113 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2612545154","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612545154?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:29","pubTimestamp":1771331353,"startTime":"0","endTime":"0","summary":"GRAIL (GRAL) has an average rating of overweight and mean price target of $114.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2612566464","title":"Grail Initiated at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2612566464","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612566464?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:07","pubTimestamp":1771326420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GRAL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 06:07 ET (11:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2612455568","title":"Grail initiated with an Outperform at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2612455568","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612455568?lang=en_us&edition=fundamental","pubTime":"2026-02-17 18:15","pubTimestamp":1771323313,"startTime":"0","endTime":"0","summary":"Baird initiated coverage of Grail (GRAL) with an Outperform rating and $113 price target Grail is a commercial-stage healthcare company focused on ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-initiated-with-an-outperform-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-initiated-with-an-outperform-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2611485234","title":"Grail Inc. to Announce Fourth Quarter and Full Year Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2611485234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611485234?lang=en_us&edition=fundamental","pubTime":"2026-02-16 22:00","pubTimestamp":1771250435,"startTime":"0","endTime":"0","summary":"Grail Inc. to Announce Fourth Quarter and Full Year Financial Results               GRAIL, Inc. will announce its fourth quarter and full year 2025 financial results after market close on Thursday, Fe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nNDLcbHb62:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2609753512","title":"Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2609753512","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609753512?lang=en_us&edition=fundamental","pubTime":"2026-02-07 06:41","pubTimestamp":1770417660,"startTime":"0","endTime":"0","summary":"A new Super Bowl ad from Hims & Hers is giving some medical experts pause. In addition to touting the company's weight loss drugs and testosterone treatments, it promotes a controversial early cancer detection test.Hims & Hers charges $689 for the test, which involves a blood draw and a prescription by a medical professional. It isn't approved by the Food and Drug Administration, nor is it covered by Medicare and most health insurance plans. However, the test's manufacturer, Grail, recently applied for premarket approval for it from the FDA and new federal legislation creates a pathway for Medicare coverage.The test, known as the Galleri multi-cancer early detection  test, promises to detect up to 50 different cancers before symptoms appear. Exact Sciences, maker of the colon cancer screening test Cologuard, released a competing product called Cancerguard last fall for $89, while Cancer Check Labs offers one that screens for some 200 kinds of cancers for $1,995.This content was created","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMS","BK4196","BK4585","LU1861558580.USD","LU2324357040.USD","LU1861559042.SGD","BK4139","BK4548","LU0266013472.USD","GRAL","BK4588"],"gpt_icon":1},{"id":"2608367107","title":"Hims & Hers Health kooperiert mit GRAIL für Multi-Krebs-Früherkennungstest","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367107","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367107?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:01","pubTimestamp":1770213663,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc. published the original content used to generate this news brief via Business Wire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"74060e00a21b1d65e69f351ee867338d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDLc6CHyP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","HIMS","BK4139","GRAL"],"gpt_icon":1},{"id":"2607635540","title":"Grail submits FDA premarket approval appplication for Galleri","url":"https://stock-news.laohu8.com/highlight/detail?id=2607635540","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607635540?lang=en_us&edition=fundamental","pubTime":"2026-01-30 08:35","pubTimestamp":1769733319,"startTime":"0","endTime":"0","summary":"GRAIL (GRAL) “announced the submission of the final module of the Premarket Approval application to the U.S. Food and Drug Administration for its G...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-submits-fda-premarket-approval-appplication-for-galleri-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-submits-fda-premarket-approval-appplication-for-galleri-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2607068956","title":"Grail Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2607068956","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607068956?lang=en_us&edition=fundamental","pubTime":"2026-01-30 08:25","pubTimestamp":1769732714,"startTime":"0","endTime":"0","summary":"GRAIL, Inc. has submitted the final module of its Premarket Approval  application to the U.S. Food and Drug Administration  for the Galleri multi-cancer early detection  test. The Galleri test, which was designated as a Breakthrough Device by the FDA in 2018, aims to improve early cancer detection. The PMA submission is based on test performance and safety data from 25,490 participants in the US-based PATHFINDER 2 study and the first year of the NHS-Galleri trial. A bridging analysis comparing different versions of the Galleri test was also included to support the application.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire  on January 30, 2026, a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL558T3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2606242930","title":"Grail Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2606242930","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606242930?lang=en_us&edition=fundamental","pubTime":"2026-01-27 00:46","pubTimestamp":1769445960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GRAL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 26, 2026 11:46 ET (16:46 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2605794409","title":"Grail falls -9.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605794409","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605794409?lang=en_us&edition=fundamental","pubTime":"2026-01-23 23:05","pubTimestamp":1769180737,"startTime":"0","endTime":"0","summary":"Grail (GRAL) is down -9.2%, or -$10.68 to $105.39. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-falls-9-2-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-falls-9-2-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2603243632","title":"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and GRAIL Inc (GRAL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603243632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603243632?lang=en_us&edition=fundamental","pubTime":"2026-01-14 03:10","pubTimestamp":1768331418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and GRAIL I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-grail-inc-gral-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-grail-inc-gral-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1066053197.SGD","BK4566","LU1571399168.USD","LU1839511570.USD","IE00BZ1G4Q59.USD","SG9999015945.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","BK4137","LU2468319806.SGD","BK4585","LU1430594728.SGD","LU0320765992.SGD","LU1674673691.USD","IE00B19Z3B42.SGD","LU0823416689.USD","BK4139","SG9999015952.SGD","BK4583","SG9999015986.USD","LU0114720955.EUR","LU2324357040.USD","BK4578","BK4568","LU0289739699.SGD","HCSG","GRAL","LU2089984988.USD","SG9999015978.USD","LU1674673428.USD","BK4532","IE00BSNM7G36.USD","GILD","LU0889565916.HKD","IE00BKVL7J92.USD","XBI","XLV","LU1585245621.USD","LABU","IE00B3T34201.USD","LU0109394709.USD","LU0234570918.USD","LU2087621335.USD","LU0882574055.USD","BK4550","BK4581","LU1066051498.USD","LU0128526141.USD","BK4588","IE0002270589.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":141,"code":"91000000","status":"200"}]}}